Free Trial

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences logo
$113.18 +0.89 (+0.79%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$113.07 -0.11 (-0.10%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
8
Buy
18

Based on 26 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 8 have given a hold rating, 15 have given a buy rating, and 3 have given a strong buy rating for GILD.

Consensus Price Target

$112.36
-0.72% Downside
According to the 26 analysts' twelve-month price targets for Gilead Sciences, the average price target is $112.36. The highest price target for GILD is $140.00, while the lowest price target for GILD is $90.00. The average price target represents a forecasted downside of -0.72% from the current price of $113.18.
Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

Sign Up

GILD Analyst Ratings Over Time

TypeCurrent Forecast
8/2/24 to 8/2/25
1 Month Ago
7/3/24 to 7/3/25
3 Months Ago
5/4/24 to 5/4/25
1 Year Ago
8/3/23 to 8/2/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
12 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$112.36$110.55$110.55$81.81
Forecasted Upside-0.72% Downside-0.66% Downside6.62% Upside6.57% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gilead Sciences Stock vs. The Competition

TypeGilead SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-0.72% Downside10,285.39% Upside14.62% Upside
News Sentiment Rating
Positive News

See Recent GILD News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/25/2025Needham & Company LLC
2 of 5 stars
Joseph Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$133.00+17.49%
4/25/2025Morgan Stanley
3 of 5 stars
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$130.00 ➝ $135.00+30.24%
4/25/2025Oppenheimer
2 of 5 stars
Hartaj Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$132.00 ➝ $125.00+20.59%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$125.00+19.81%
3/27/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Schott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$120.00 ➝ $130.00+17.10%
3/5/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tim Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$116.00 ➝ $126.00+9.00%
3/5/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$120.00 ➝ $140.00+21.20%
2/18/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
James Shin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$80.00 ➝ $120.00+15.30%
2/13/2025DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$108.00+4.54%
2/12/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Salveen Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$85.00 ➝ $96.00-7.27%
2/12/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Perform ➝ Sector Perform$84.00 ➝ $90.00-13.06%
2/12/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Evan Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$110.00 ➝ $115.00+10.74%
2/12/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joseph Catanzaro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$105.00 ➝ $110.00+6.33%
11/21/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$70.00 ➝ $96.00+6.95%
11/21/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$90.00 ➝ $100.00+12.83%
11/18/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$110.00+19.42%
11/14/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$125.00+34.95%
11/8/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$83.00 ➝ $97.00
11/8/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Okunewitch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
11/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$80.00 ➝ $95.00-2.30%
11/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$84.00 ➝ $95.00-1.72%
10/21/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/21/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$74.00 ➝ $96.00+10.70%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$105.00+21.04%
8/9/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
U. Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/8/2024Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$93.00+39.45%
4/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$90.00 ➝ $85.00+29.99%
4/24/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold$69.00+2.99%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:25 AM ET.


Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, July 31, 2025. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • Recent analyst upgrades have been positive, with multiple firms raising their price targets, indicating strong market confidence in Gilead Sciences, Inc.'s future performance.
  • The current stock price is around $111, which may present a buying opportunity for investors looking to enter at a favorable valuation.
  • Gilead Sciences, Inc. has a consensus rating of "Moderate Buy," suggesting that a majority of analysts believe the stock is a good investment.
  • With a significant number of analysts issuing buy ratings, there is potential for upward momentum in the stock price as market sentiment improves.
  • The company is actively involved in developing innovative treatments, which could lead to substantial revenue growth in the future.

Gilead Sciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • Insider selling has been notable, with significant shares sold recently, which may indicate a lack of confidence from those within the company.
  • Despite positive ratings, the average price target remains lower than some recent highs, suggesting potential limitations on short-term price appreciation.
  • Market volatility can impact biopharmaceutical stocks significantly, and Gilead Sciences, Inc. is not immune to broader market fluctuations.
  • There is a relatively small percentage of stock owned by insiders, which may raise concerns about alignment between management and shareholder interests.
  • Recent price adjustments by analysts, including downgrades from some firms, could signal caution among investors regarding the stock's near-term performance.

GILD Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $112.36, with a high forecast of $140.00 and a low forecast of $90.00.

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 8 hold ratings, 15 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GILD shares.

According to analysts, Gilead Sciences's stock has a predicted downside of -0.72% based on their 12-month stock forecasts.

Over the previous 90 days, Gilead Sciences's stock had 1 upgrade by analysts.

Gilead Sciences has been rated by research analysts at Needham & Company LLC in the past 90 days.

Analysts like Gilead Sciences more than other "medical" companies. The consensus rating score for Gilead Sciences is 2.81 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GILD compares to other companies.


This page (NASDAQ:GILD) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners